CORC

浏览/检索结果: 共5条,第1-5条 帮助

限定条件                    
已选(0)清除 条数/页:   排序方式:
Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM-3002 study 期刊论文
Blood, 2014, 卷号: 124
作者:  Robak T., Huang H., Jin J., Zhu J., Liu T., Samoilova O.S., Pylypenko H., Verhoef G., Siritanaratkul N., Osmanov E.A., Alexeeva J., Pereira J., Mayer J., Hong X., Maeda Y., Pei L., Rooney B., Van De V
收藏  |  浏览/下载:4/0  |  提交时间:2019/12/19
Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 期刊论文
LANCET, 2014, 卷号: 384, 期号: 9947
作者:  Wang, Haidong;  Liddell, Chelsea A.;  Coates, Matthew M.;  Mooney, Meghan D.;  Levitz, Carly E.
收藏  |  浏览/下载:9/0  |  提交时间:2019/12/19
Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 期刊论文
LANCET, 2014, 卷号: 384, 期号: 9947
作者:  Murray, Christopher J. L.;  Ortblad, Katrina F.;  Guinovart, Caterina;  Lim, Stephen S.;  Wolock, Timothy M.
收藏  |  浏览/下载:10/0  |  提交时间:2019/12/19
PHASE 3 STUDY OF FRONTLINE RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE PLUS VINCRISTINE (R-CHOP) OR BORTEZOMIB (VR-CAP) IN TRANSPLANTATION-UNSUITABLE MANTLE CELL LYMPHOMA (MCL) PATIENTS 会议论文
作者:  Robak, T.;  Huang, H.;  Jin, J.;  Zhu, J.;  Liu, T.
收藏  |  浏览/下载:5/0  |  提交时间:2019/12/19
Huntingtin gene CAG repeat numbers in Chinese patients with Huntington's disease and controls 期刊论文
EUROPEAN JOURNAL OF NEUROLOGY, 2014, 卷号: 21, 期号: 4
作者:  Jiang, H.;  Sun, Y. M.;  Hao, Y.;  Yan, Y. P.;  Chen, K.
收藏  |  浏览/下载:7/0  |  提交时间:2019/12/19


©版权所有 ©2017 CSpace - Powered by CSpace